Gene Panel Global Market Report 2025

Gene panels are a set of specific genes selected for testing in a single assay to analyze genetic variations associated with particular diseases or conditions. They are utilized for diagnosing genetic disorders, detecting inherited diseases, and enabling personalized treatment plans by examining multiple genes simultaneously, particularly in cancer, rare diseases, and other genetic conditions.

The primary gene panel products and services include test kits and testing services. Test kits are pre-packaged tools containing all necessary reagents and instructions for genetic analysis. These panels employ various technologies, such as amplicon-based and hybridization-based methods, and can be either predesigned or customized. They are applied in cancer risk assessment, congenital disease diagnosis, pharmacogenetics, and other areas, serving end users such as research institutes, hospitals, diagnostic centers, pharmaceutical companies, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The gene panel market research report is one of a series of new reports from The Business Research Company that provides gene panel market statistics, including gene panel industry global market size, regional shares, competitors with a gene panel market share, detailed gene panel market segments, market trends and opportunities, and any further data you may need to thrive in the gene panel industry. This gene panel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gene panel market size has grown rapidly in recent years. It will grow from $2.14 billion in 2024 to $2.47 billion in 2025 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to the rising prevalence of hereditary disorders, growing necessity for genetic screening, increasing research and development activities, rising prevalence of congenital diseases, and increasing demand for advanced treatment options.

The gene panel market size is expected to see rapid growth in the next few years. It will grow to $4.33 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to an increasing number of chronic diseases, increasing cancer cases, increasing awareness of genetic testing, and increasing government initiatives and healthcare spending. Major trends in the forecast period include the advancement of gene panel technology, strategic collaboration, personalized treatment, the integration of artificial intelligence, and advanced bioinformatics tools.

The forecast of 15.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of next-generation sequencing (NGS) gene panels sourced from South Korea and the UK, thereby delaying genetic disease diagnoses and elevating molecular pathology lab expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of cancer is expected to drive the growth of the gene panel market. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which can invade and damage surrounding tissues and organs. Factors such as aging populations, lifestyle changes, environmental exposures, and advancements in detection and diagnostic technologies are contributing to the increasing number of cancer cases. Gene panels play a crucial role in cancer diagnosis by enabling comprehensive genetic testing to identify mutations and alterations in specific genes, facilitating personalized treatment strategies and improving patient outcomes. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that an estimated 9.7 million people died from cancer in 2022, with 20 million new cases recorded. Lung cancer was the most prevalent, accounting for 12.4% of all new cases, with 2.5 million diagnoses worldwide. This increasing cancer burden continues to drive demand for gene panel testing.

Leading companies in the gene panel market are focusing on developing advanced oncology panels to enhance the accuracy, efficiency, and comprehensiveness of cancer diagnostics and personalized treatment approaches. Oncology panels are specialized gene panels that analyze multiple genes associated with cancer, identifying genetic mutations and alterations to aid in diagnosis, prognosis, and treatment planning. For instance, in May 2023, Vizgen Inc., a US-based biotechnology company, introduced the MERFISH PanCancer Pathways Panel, providing a customizable option for scientists exploring spatial genomics. These predesigned panels are optimized for various research applications, including cancer studies, and offer enhanced error robustness for reliable and reproducible results. By integrating spatial information with gene expression data, the panels provide deeper insights into tumor microenvironments and cellular interactions, advancing targeted cancer research and therapeutic development. This innovation marks a significant breakthrough in spatial biology, allowing researchers to analyze complex biological systems with unprecedented detail.

In May 2022, Sema4, a US-based health intelligence company, acquired GeneDx in a $322 million transaction. This acquisition bolsters Sema4's position as a leading provider of genomic testing in the U.S., enhancing its health information database to improve patient care and therapeutic development. GeneDx, also based in the U.S., specializes in comprehensive diagnostic services for rare genetic disorders, inherited diseases, and cancers, further strengthening Sema4's capabilities in precision medicine.

Major players in the gene panel market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Intermountain Healthcare, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., OPKO Health Inc., Myriad Genetics Inc., Guardant Health Inc., Invitae Corp., Integrated DNA Technologies Inc., Bio-Rad Laboratories Inc., Novogene Corporation, Fulgent Genetics Inc., MedGenome Inc., OriGene Technologies Inc., Centogene AG, Blueprint Genetics Inc., BIONEER Corporation, BGI Group Ltd., Vizgen Inc., Primbio Research Institute LLC.

North America was the largest region in the gene panel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene panel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gene panel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gene panel market consists of revenues earned by entities by providing services such as custom panel design, next-generation sequencing, bioinformatics analysis, clinical interpretation, and pharmacogenomics services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene panel market also includes sales of metabolic disorder panels, reproductive health panels, carrier screening panels, and neurological disorder panels. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gene Panel Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gene panel market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gene panel ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gene panel market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product And Services: Test Kits; Testing Services
• 2) By Technology: Amplicon-Based; Hybridization-Based; Other Technologies
• 3) By Design: Predesigned Gene Panel; Customized Gene Panel
• 4) By Application: Cancer Risk Assessment; Diagnosis Of Congenital Diseases; Pharmacogenetics; Other Applications
• 5) By End-User: Research Institutes; Hospital; Diagnosis Centers; Pharmaceutical Companies; Other End-Users
• Subsegments:
• 1) By Test Kits: Predesigned Gene Panels; Customized Gene Panels
• 2) By Testing Services: Cancer Risk Assessment Panels; Pharmacogenetic Testing Panels; Neurological Disorder Panels; Cardiovascular Disease Panels; Rare Disease Panels
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Quest Diagnostics Inc.; Intermountain Healthcare; Eurofins Scientific SE; Agilent Technologies Inc.; Illumina Inc.; Qiagen Inc.; OPKO Health Inc.; Myriad Genetics Inc.; Guardant Health Inc.; Invitae Corp.; Integrated DNA Technologies Inc.; Bio-Rad Laboratories Inc.; Novogene Corporation; Fulgent Genetics Inc.; MedGenome Inc.; OriGene Technologies Inc.; Centogene AG; Blueprint Genetics Inc.; BIONEER Corporation; BGI Group Ltd.; Vizgen Inc.; Primbio Research Institute LLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.